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BACKGROUND: Bone morphogenetic protein-7 (BMP-7) is a signalling molecule belonging to the transforming growth
factor–superfamily. Recent studies have demonstrated the clinical impact of BMP-7 expression in various human cancers. However,
there have been few reports detailing this in gastric cancer.
METHODS: We immunohistochemically investigated the expression of BMP-7 in 233 gastric cancer patients to disclose
the clinicopathological features of BMP-7-positive gastric cancer.
RESULTS: Immunohistochemically, in human gastric cancer, BMP-7 expression was identified in cellular membranes but also in
the cytoplasm of cancer cells. Bone morphogenetic protein-7-positive expression was found in 129 of 233 patients (55%).
Bone morphogenetic protein-7 expression was correlated with tumour size, nodal involvement, lymphatic invasion, venous invasion
and histology (Po0.05). Bone morphogenetic protein-7 expression was significantly correlated with patient postoperative outcome,
especially in the undifferentiated group. Multivariate analysis revealed BMP-7 expression as one of the independent prognostic factors
next to the depth of invasion and nodal involvement (Po0.01).
CONCLUSIONS: From the data collected, it would be appropriate to conclude on the possible regulation of gastric cancer progression
by autocrine or paracrine BMP-7 loops. We can use BMP-7 expression as one of the strong predictors of risk of tumour recurrence in
gastric cancer.
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Gastric cancer is the fourth most common cancer. East Asian
countries in particular, including Japan, are the most high-risk
areas for gastric cancer. In Japan, the establishment of mass
screening by photo fluoroscopy or gastrointestinal fibroscopy
has led to gastric cancer being diagnosed asymptomatically and
curatively treated with gastrectomy; the survival rate of gastric
cancer has drastically improved. However, even for patients who
have received curative surgery, the recurrence of gastric cancer
occurs (Parkin et al, 2005; Brenner et al, 2009). In this context, it is
necessary to find novel cancer-related factors to use as markers for
diagnosis and treatment of gastric cancer.
Bone morphogenetic proteins (BMPs) are signalling molecules
belonging to the transforming growth factor (TGF)–superfamily,
with 430 subtypes in mammals, Drosophila, Xenopus and sea
urchin (Wozney et al, 1988; Ducy and Karsenty, 2000). Bone
morphogenetic proteins were originally identified as cytokines
inducing ectopic chondro-osteogenesis and have a role in skeletal
and joint morphogenesis, bone remodelling and fracture repair
(Urist, 1965; Chen et al, 2004). However, the function of BMPs is
linked not only to bone tissue, but also to cellular homeostasis and
embryonic development. Several studies demonstrated that mice
deficient in different BMPs exhibited impairments and abnorm-
alities of various organs (Dudley et al, 1995; Luo et al, 1995;
McPherron et al, 1997; Solloway and Robertson, 1999).
Expression of BMP-7 is highest in the kidney and it is thought to
be related to kidney and eye development and skeletal patterning
(Dudley et al, 1995; Luo et al, 1995). Moreover, BMP-7 reverses
chronic renal injury by counteracting TGF-1-induced epithelial-to-
mesenchymal transition (Zeisberg et al, 2003). Recent studies
demonstrated that BMP-7 expression is found in various human
cancers, and regulates cell differentiation, proliferation, migration,
invasion and apoptosis (Andrews et al, 1994; Ro et al, 2004;
Yang et al, 2005, 2006; Grijelmo et al, 2007; Alarmo et al, 2009).
However, to our knowledge, there have been no reports demon-
strating the association between BMP-7 expression and clinico-
pathological factors including prognosis in gastric cancer. Thus,
the purpose of this study was to investigate BMP-7 expression by
immunohistochemistry in gastric cancer and evaluate the clinical
impact of BMP-7-positive gastric cancer.
MATERIALS AND METHODS
Detection of mRNA expression of BMP-7 in gastric
cancer cell lines
We used five gastric cancer cell lines (KATOIII, NUGC-4, MKN45,
MKN74 and MKN7 (Riken Cell Bank, Tsukuba, Japan)) to detect
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smRNA expression of BMP-7 by RT–PCR. First, five gastric cancer
cell lines were cultured in RPMI-1640 (Sigma-Aldrich Co., St Louis,
MO, USA) supplemented with antibiotics (100unitsml
–1penicillin
and 100mgml
–1 streptomycin) and 10% fetal bovine serum
(MBL, Nagoya, Japan) at 371C in a humidified atmosphere of
5% CO2 in air. Proliferated cells were used to detect mRNA
expression of BMP-7. Total RNA was extracted from the cell lines
using RN easy Mini-Kit (Qiagen, Valencia, CA, USA) according to
the manufacturer’s instructions. Complementary DNA (0.05mgml
–1)
was synthesised as described previously (Yokomakura et al, 2007).
Amplification of BMP-7 and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) cDNA was performed in a total volume of 30ml,
which included 1ml of the cDNA product sample, 0.5mM each of
BMP-7 primer (Roche, Mannheim, Germany) and GAPDH
primer (forward primer: 50-TTGGTATCGTGGAAGGACTCA-30
and reverse primer: 50-TGTCATCATATTTGGCAGGTTT-30),
GeneAmp 10  PCR Buffer (Applied Biosystems, Foster City,
CA, USA), 0.5 U AmpliTaq DNA polymerase (Applied Biosystems)
and 25mM dNTP mixture (Takara Bio Inc., Otsu, Japan).
The GAPDH gene served as an internal control. The BMP-7
and GAPDH amplification reactions were 30 cycles (BMP-7)o r
26 cycles (GAPDH) of denaturation at 941C for 60s (BMP-7)o r
30s (GAPDH), annealing at 641C for 60s (BMP-7)o r5 41C for 30s
(GAPDH), and elongation at 721C for 60s (BMP-7)o r3 0 s
(GAPDH) in the GeneAmp PCR System 9700 (Applied Biosystems).
Amplified DNA fragments were electrophoresed on 1.5% agarose
gels containing ethidium bromide with a DNA molecular weight
marker for comparison.
Patients and specimens
This study included 233 patients with gastric adenocarcinoma
invading deeper than the submucosal layer. All patients underwent
curative gastrectomy with lymph node dissection at Kagoshima
University Hospital from January 1995 to December 2004 (Table 1).
In all, 75 patients underwent distal, 21 proximal, 124 total and 13
partial gastrectomy. A total of 233 gastric cancer patients were
classified, including 161 male and 72 female patients (range, 31–85
years; average, 66 years). The final pathological examination
disclosed that cases of stage I, II, III and IV gastric cancers
numbered 70, 45, 63 and 55, respectively. The patients were
histopathologically classified as 118 differentiated (papillary,
well-differentiated and moderately differentiated tubular
adenocarcinoma) or 115 undifferentiated (poorly differentiated
adenocarcinoma, mucinous adenocarcinoma and signet-ring cell
carcinoma) according to the Japanese classification of gastric
cancer (Japanese Gastric Cancer Association, 1998). The study was
approved by the Institutional Review Board of Kagoshima
University and performed according to the Helsinki Declaration.
Immunohistochemistry of BMP-7 in gastric cancer
and its evaluation
The specimens of the gastric cancer were formalin-fixed and
paraffin-embedded tissues; they were cut into 3-mm-thick sections
and mounted on glass slides for immunohistochemistry. They were
deparaffinised in xylene and dehydrated with a series of graded
ethanol. The endogenous peroxidase activity of specimens
was blocked by immersing the slides in a 0.3% H2O2 solution in
methanol for 30min at room temperature. After washing three
times with phosphate-buffered saline (PBS) for 5min each, the
sections were treated with 1% bovine serum albumin for 30min to
block nonspecific reactions at room temperature. The blocked
sections were incubated with the mouse monoclonal antibody
against human BMP-7 (1:500; R&D Systems, Inc., Minneapolis,
MN, USA) and left 24h at 41C, followed by staining with a
streptavidin–biotin peroxidase kit (Vector Laboratories, Inc.,
Burlingame, CA, USA). The sections were washed in PBS for
5min three times and the immune complex was visualised by
incubating the sections with diaminobenzidine tetrahydrochloride.
The sections were rinsed briefly in water, counterstained with
haematoxylin and mounted. Noncancerous kidney samples were
used as positive controls for BMP-7. Bone morphogenetic protein-7
expression was determined by counting the number of cancer cells
in which the cytoplasm was stained with the anti-BMP-7 antibody.
Evaluation of immunohistochemistry was independently carried
out by two investigators (MA and SI). To evaluate this,
10 fields within the tumour were selected, and expression in
1000 cancer cells (100 cells per field) was evaluated using high-
power ( 200) microscopy. The average labelling index of BMP-7
was assessed according to the proportion of positive cells in each
field. Bone morphogenetic protein-7 expression was graded as the
BMP-7-positive group if 410% of cancer cells were stained or as
the BMP-7-negative group if o10% of cancer cells were stained.
Statistical analysis
A statistical analysis of group differences was performed using w
2
test. The Kaplan–Meier method was used for survival analysis and
evaluated by the log-rank test. The Cox proportional hazard model
was used in multivariate analysis. Po0.05 was considered
statistically significant.
RESULTS
BMP-7 expression in gastric cancer and its association
with clinical results
Immunohistochemically, in human gastric cancer, BMP-7 expres-
sion was identified in cellular membranes but also in the
cytoplasm of cancer cells (Figure 1). According to the immuno-
histochemical evaluation, 129 of 233 patients (55%) were placed in
the BMP-7-positive group. Bone morphogenetic protein-7
expression correlated with clinicopathological variables. Namely,
tumour diameter, nodal involvement, lymphatic invasion and
venous invasion were significantly greater in the BMP-7-positive
group than in the BMP-7-negative group (P¼0.01, o0.01, o0.01
and o0.01, respectively). Moreover, BMP-7 expression was
significantly higher in the differentiated histology group than in
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sthe undifferentiated group (Po0.05). No significant difference was
observed regarding age, gender or tumour depth (Table 2). The
overall survival rate was significantly lower in the BMP-7-positive
group than in the BMP-7-negative group (Po0.01; Figure 2A).
Furthermore, we evaluated the correlation between expression of
BMP-7 and prognosis in the differentiated and the undifferentiated
histology groups. In the differentiated histology group, BMP-7
expression was not associated with postoperative outcome
(Figure 2B). On the other hand, in the undifferentiated group,
the BMP-7-positive group had significantly poorer survival than
the BMP-7-negative group (P¼0.01) (Figure 2C).
Univariate and multivariate analyses of survival
Table 3 shows the results of univariate and multivariate analyses of
factors related to patient prognosis. Univariate analysis showed
that tumour histology, the depth of invasion, tumour size, lymph
node metastasis, lymphatic invasion, venous invasion and BMP-7
expression were significantly related to postoperative survival
(Po0.01). Multivariate analysis indicated that BMP-7 expression
was one of the independent prognostic factors of overall survival
for the patients with gastric cancer next to the depth of invasion
and nodal involvement (Po0.01).
DISCUSSION
Bone morphogenetic protein-7 induces differentiation of mesen-
chymal cells to osteoblastic cells in bone and cartilage tissue (Ducy
and Karsenty, 2000). Moreover, in kidney, it is related to MET and
reverses chronic renal injury (Zeisberg et al, 2003). On the other
hand, BMP-7 expression has been identified and clinical features of
BMP-7 expression in several human cancers such as osteosarcoma,
malignant melanoma, breast cancer, prostate cancer, colorectal
cancer and renal cell cancer have been discussed (Sulzbacher et al,





Figure 1 Expression of BMP-7 in clinical samples. Immunostaining of BMP-7 (original magnification,  400): Examples of (A) noncancerous kidney tissue,
(B) noncancerous gastric epithelium, (C) BMP-7-positive gastric cancer and (D) BMP-7-negative gastric cancer are shown. Staining is detected in cell
membranes and the cytoplasm (A, C; they obviously stain brown).








o65 40 (48) 44 0.08
X65 89 (60) 60
Gender
Male 94 (58) 67 0.2
Female 35 (49) 37
Tumour size
o50mm 40 (44) 50 0.01
X50mm 89 (62) 54
Depth
T1 (sm)/T2 (mp) 85 (57) 65 0.68
T3 (ss)/T4 (se) 44 (53) 39
Nodal involvement
Yes 87 (63) 52 o0.01
No 42 (45) 52
Lymphatic invasion
Yes 107 (61) 69 o0.01
No 22 (39) 35
Venous invasion
Yes 88 (67) 44 o0.01
No 41 (41) 60
Histology
Differentiated 73 (62) 45 o0.05
Undifferentiated 56 (49) 59
Abbreviation: BMP-7¼bone morphogenetic protein-7.
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sRothhammer et al, 2007; Motoyama et al, 2008 ). In this study,
robust expression of the BMP-7 mRNA was identified by RT–PCR
in MKN45 and MKN74 gastric cancer cell lines, which were derived
from liver metastasis (data not shown).
We showed that BMP-7 expression was significantly associated
with clinical factors such as lymphatic invasion, venous invasion
and nodal involvement. Their previous studies demonstrated that
BMP-7 promoted breast cancer cell migration and invasion,
prostate cancer cell mobility and related metastasis in colorectal
cancer (Yang et al, 2005; Grijelmo et al, 2007; Alarmo et al, 2009).
In this context, BMP-7 expression may be connected with tumour
aggressiveness beyond the specific organ. In this study, we showed
that BMP-7 expression strongly correlated with nodal involvement.
Thus, BMP-7 expression of biopsy may be informative to predict
lymph node metastasis, when we should choose between endo-
scopic resection or gastrectomy for early gastric cancer.
As a prognostic parameter, Motoyama et al (2008) reported that
overexpression of BMP-7 mRNA was significantly associated with
lower overall survival in colorectal cancer. Moreover, BMP-7
expression by immunohistochemistry was also significantly asso-
ciated with lower recurrence-free survival in malignant melanoma
and breast cancer (Rothhammer et al,2 0 0 7 ;A l a r m oet al,2 0 0 8 ) .W e
showed that BMP-7 expression in gastric cancer was an independent
prognostic marker in accordance with results for other cancers. Only
in renal cell carcinoma was BMP-7 expression significantly
associated with better surgical outcome (Kwak et al, 2007). This
may be explained by the fact that normal kidney cell usually highly
expresses BMP-7 unlike normal gastric mucosa. Such differences
might have caused the inverse result in prognostic implication.
In this study, BMP-7-positive gastric cancer was shown to be
correlated with well-differentiated tumour histology. Andrews et al
(1994) demonstrated that BMP-7-induced differentiation
of pluripotent human embryonal carcinoma cells. Moreover,
Lombardo et al (2011) reported that BMP-4-induced differentia-
tion of colorectal cancer stem cells and increased their response to
chemotherapy in mice. We demonstrated that BMP-7 expression
was a more significant prognostic factor only in the undiffer-
entiated group (Figures 2B and C). In short, although BMP-7 was
highly expressed in the BMP-7-positive and undifferentiated
group, the differentiation of this group was restricted, and the
prognosis was poor. In the undifferentiated group, other factors
that are associated with regulation of BMP signalling pathway
might be associated with this result. The BMP signalling pathway is
regulated in a complex manner by extracellular and intracellular
factors and crosstalk with other signalling pathways, including
TGF–signalling pathway (Zwijsen et al, 2003; Cao and Chen, 2005;
Gazzerro and Canalis, 2006; Lombardo et al, 2011; Luo et al, 2010).
It is necessary to further study the relationship between BMP
signalling pathway and its related factors to open the view of
chemotherapy in gastric cancer.
In conclusion, from the data collected, it would be appropriate
to conclude on the possible regulation of gastric cancer progres-
sion by autocrine or paracrine BMP-7 loops. We can use BMP-7
expression as a predictor of lymph node metastasis and post-
operative outcome in gastric cancer. As previously mentioned, the
signals activated by BMP-7 are involve intracellular and extra-
cellular factors, so further analysis seems to be necessary to
determine the mechanism involved.
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